pharmaceutical investing Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates
pharmaceutical investing Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
pharmaceutical investing Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
pharmaceutical investing Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
pharmaceutical investing Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
pharmaceutical investing Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026
pharmaceutical investing Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
pharmaceutical investing Minerva Neurosciences to Participate in The Citizens Life Sciences Conference
pharmaceutical investing Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality - Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026
pharmaceutical investing Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors
pharmaceutical investing Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
Steadright Critical Minerals Inc. to Acquire up to 75% Interest in the Péribonka Ree-Niobium Carbonatite Project, Saguenay-Lac-St-Jean Region, Québec
Prismo Metals Announces Listing of Blade Resources on the CSE Prismo Metals Owns 6,755,000 Shares of Blade Resources
Goldgroup Highlights Its Two Producing Mines and Significant Growth Potential Across the Don David Gold Complex in Mexico
